Phase I results for a unique formulation of the anti-inflammatory painkiller naproxen have been announced.
Iroko Pharmaceuticals has developed a new form of the widely used pain medication with its proprietary, patented nanotechnology.
The comparator products used in this Phase I pharmacokinetic study of naproxen were identified as Naprosyn® and EC-Naprosyn®, a currently marketed enteric-coated brand of naproxen.
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used for the reduction of pain, fever, inflammation and stiffness caused by osteoarthritis among other conditions.
Iroko is a pharmaceutical company committed to the development and commercialization of currently marketed pharmaceutical products in specialty therapeutic areas.
EC-Naprosyn® and Naprosyn® are registered trademarks of Syntex Pharmaceuticals International Limited.